Request Demo
Last update 03 Dec 2025
MT-1002
Last update 03 Dec 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms MT-1002, MT1002 |
Target |
Action antagonists, inhibitors |
Mechanism GP IIb/IIIa antagonists(Integrin alpha-IIb/beta-3 antagonists), thrombin inhibitors(Factor IIa inhibitors) |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with MT-1002NCT06533358
An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
NCT05323136
A Phase 1, Open-Label, Sequential, Adaptive, Single Dose Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of MT1002 for Injection
CTR20212162
一项随机双盲，安慰剂对照，在健康受试者人群序贯给予MT1002 的单剂量爬坡的安全性、耐受性、药代动力学和药效学的 Ι 期临床研究
[Translation] A randomized, double-blind, placebo-controlled, Phase I clinical study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of sequential single-dose escalation of MT1002 in healthy subjects
100 Clinical Results associated with MT-1002
Login to view more data
100 Translational Medicine associated with MT-1002
Login to view more data
100 Patents (Medical) associated with MT-1002
Login to view more data
100 Deals associated with MT-1002
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Coronary Syndrome | Phase 2 | United States | 02 Dec 2020 | |
| Non-St Elevated Myocardial Infarction | Phase 2 | United States | 02 Dec 2020 | |
| Stroke | Phase 2 | China | - | |
| Venous Thromboembolism | Phase 2 | China | - | |
| Heparin-induced thrombocytopenia | Phase 1 | China | 18 Sep 2021 | |
| Thrombosis | Phase 1 | China | 18 Sep 2021 | |
| Acute Ischemic Stroke | IND Approval | China | 26 Jun 2023 | |
| Blood Coagulation Disorders | IND Approval | China | 07 Jun 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free